Nitric oxide and aspirin: A new mediator for an old drug

American Journal of Therapeutics

Volumn 16, Issue 1, 2009, Pages 17-23

  Schröder, Henning ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Antioxidant; Bilirubin; Ferritin; Heme oxygenase 1

Indexed keywords

ACETYLSALICYLIC ACID; ENDOTHELIAL NITRIC OXIDE SYNTHASE; HEME OXYGENASE 1; LIPOXIN; NITRIC OXIDE; NONSTEROID ANTIINFLAMMATORY AGENT;

ACETYLATION; CELL PROTECTION; DEGENERATIVE DISEASE; DRUG MECHANISM; DRUG SAFETY; ENZYME ACTIVATION; FEVER; HEART INFARCTION; HUMAN; INFLAMMATION; LOW DRUG DOSE; NEOPLASM; NONHUMAN; PAIN; PRIORITY JOURNAL; REVIEW; STOMACH HEMORRHAGE; STOMACH IRRITATION; STROKE;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIOXIDANTS; ASPIRIN; CYCLOOXYGENASE INHIBITORS; FERRITINS; HEME OXYGENASE-1; HUMANS; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE III;

EID: 60249094622     PISSN: 10752765     EISSN: None     Source Type: Journal    
DOI: 10.1097/MJT.0b013e318164bd60     Document Type: Review

References (83)

1. Fuster V, Dyken ML, Vokonas PS, et al. Aspirin as a therapeutic agent in cardiovascular disease. Circulation. 1993;87:659-675.
2. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324:71-86.
3. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol. 1971;231:232-235.
4. Vane JR, Botting RM. The mechanism of action of aspirin. Thromb Res. 2003;110:255-258.
5. Samuelsson B, Granstrom E, Green K, et al. Prostaglandins. Annu Rev Biochem. 1975;44:669-695.
6. Reilly IA, FitzGerald GA. Aspirin in cardiovascular disease. Drugs. 1988;35:154-176.
7. Aruoma OI, Halliwell B. The iron-binding and hydroxyl radical scavenging action of anti-inflammatory drugs. Xenobiotica. 1988;18:459-470.
8. Woollard AC, Wolff SP, Bascal ZA. Antioxidant characteristics of some potential anticataract agents. Studies of aspirin, paracetamol, and bendazac provide support for an oxidative component of cataract. Free Radic Biol Med. 1990;9:299-305.
9. Podhaisky HP, Abate A, Polte T, et al. Aspirin protects endothelial cells from oxidative stress-possible synergism with vitamin E. FEBS Lett. 1997;417:349-351.
10. Steer KA, Wallace TM, Bolton CH, et al. Aspirin protects low density lipoprotein from oxidative modification. Heart. 1997;77:333-337.
11. Wu R, Lamontagne D, de Champlain J. Antioxidative properties of acetylsalicylic acid on vascular tissues from normotensive and spontaneously hypertensive rats. Circulation. 2002;105:387-392.
12. Wink DA, Hanbauer I, Krishna MC, et al. Nitric oxide protects against cellular damage and cytotoxicity from reactive oxygen species. Proc Natl Acad Sci USA. 1993;90:9813-9817.
13. Chang J, Rao NV, Markewitz BA, et al. Nitric oxide donor prevents hydrogen peroxide-mediated endothelial cell injury. Am J Physiol. 1996;270:L931-L940.
14. Polte T, Oberle S, Schroder H. Nitric oxide protects endothelial cells from tumor necrosis factor- alpha-mediated cytotoxicity: possible involvement of cyclic GMP. FEBS Lett. 1997;409:46-48.
15. Oberle S, Schröder H. Ferritin may mediate SIN-1-induced protection against oxidative stress. Nitric Oxide. 1997;1:308-314.
16. Fernandez-Tome P, Lizasoain I, Leza JC, et al. Neuroprotective effects of DETA-NONOate, a nitric oxide donor, on hydrogen peroxide-induced neurotoxicity in cortical neurones. Neuropharmacology. 1999;38:1307-1315.
17. Motterlini R, Foresti R, Intaglietta M, et al. NO-mediated activation of heme oxygenase: endogenous cytoprotec-tion against oxidative stress to endothelium. Am J Physiol.1996;270:H107-H114.
18. Oberle S, Polte T, Abate A, et al. Aspirin increases ferritin synthesis in endothelial cells: a novel antioxidant pathway. Circ Res. 1998;82:1016-1020.
19. Grosser N, Schröder H. Aspirin protects endothelial cells from oxidant damage via the nitric oxide-cGMP pathway. Arterioscler Thromb Vase Biol. 2003;23:1345-1351.
20. Taubert D, Berkels R, Grosser N, et al. Aspirin induces endothelial nitric oxide release-a novel mechanism of action. Br J Pharmacol. 2004;143:159-165.
21. Schroder H, Leitman DC, Bennett BM, et al. Glyceryl trinitrate-induced desensitization of guanylate cyclase in cultured rat lung fibroblasts. J Pharmacol Exp Ther. 1988;245:413-18.
22. Schröder H, Leitman D, Hayward L, et al. Cultured rat lung fibroblasts as a model for organic nitrate-induced cyclic GMP accumulation and activation of guanylate cyclase. J Appl Cardiol. 1987;2:301-311.
23. Ishii K, Sheng H, Warner TD, et al. A simple and sensitive bioassay method for detection of EDRF with RFL-6 rat lung fibroblasts. Am J Physiol. 1991;261:H598-H603.
24. Patrono C. Aspirin and human platelets: from clinical trials to acetylation of cyclooxygenase and back. Trends Pharmacol Sci. 1989;10:453-158.
25. 2 but not of systemic prostacyclin by controlled-release aspirin. N Engl J Med. 1991;325:1137-1141.
26. Kopp E, Ghosh S. Inhibition of NF-kappa B by sodium salicylate and aspirin. Science. 1994;265:956-959.
27. Weber C, Erl W, Pietsch A, et al. Aspirin inhibits nuclear factor-kappa B mobilization and monocyte adhesion in stimulated human endothelial cells. Circulation. 1995;91:1914-1917.
28. Shackelford RE, Alford PB, Xue Y, et al. Aspirin inhibits tumor necrosis factor-alpha gene expression in murine tissue macrophages. Mol Pharmacol. 1997;52:421-29.
29. Amin AR, Vyas P, Attur M, et al. The mode of action of aspirin-like drugs: effect on inducible nitric oxide synthase. Proc Natl Acad Sci USA. 1995;92:7926-7930.
30. Kwon G, Hill JR, Corbett JA, et al. Effects of aspirin on nitric oxide formation and de novo protein synthesis by RINm5F cells and rat islets. Mol Pharmacol. 1997;52:398-405.
31. Wu KK. Control of COX-2 and iNOS gene expressions by aspirin and salicylate. Thromb Res. 2003;110:273-276.
32. Dimmeler S, Fleming I, Fisslthaler B, et al. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature. 1999;399:601-605.
33. Boo YC, Sorescu G, Boyd N, et al. Shear stress stimulates phosphorylation of endothelial nitric-oxide synthase at
34. Serll79 by Akt-independent mechanisms: role of protein kinase. Am J Biol Chem. 2002;277:3388-3396.
35. Wu KK. Regulation of endothelial nitric oxide synthase activity and gene expression. Ann N Y Acad Sci. 2002;962:122-130.
36. Fleming I, Busse R. Molecular mechanisms involved in the regulation of the endothelial nitric oxide synthase. Am J Physiol. 2003;284:R1-R12.
37. Kalgutkar AS, Kozak KR, Crews BC, et al. Covalent modification of cyclooxygenase-2 (COX-2) by 2-acetoxyphenyl alkyl sulfides, a new class of selective COX-2 inactivators. J Med Chem. 1998;41:4800-4818.
38. Loll PJ, Sharkey CT, O'Connor SJ, et al. O-acetylsalicylhy-droxamic acid, a novel acetylating inhibitor of prostaglandin H2 synthase: structural and functional characterization of enzyme-inhibitor interactions. Mol Pharmacol. 2001;60:1407-1413.
39. Bridges KR, Schmidt GJ, Jensen M, et al. The acetylation of hemoglobin by aspirin. In vitro and in vivo. J Clin Invest. 1975;56:201-207.
40. Burch JW, Blazer-Yost B. Acetylation of albumin by low doses of aspirin. Thromb Res. 1981;23:447-452.
41. Green FA, Jung CY. Acetylation of erythrocytic membrane peptides by aspirin. Transfusion. 1981;21:55-58.
42. Hun-Opfer C, Mata-Segreda JF. Non-enzymatic acetylation of proteins by aspirin as protection against the secondary complications of diabetes mellitus. Acta Physiol Pharmacol Latinoam. 1986;36:313-316.
43. Ryter SW, Otterbein LE, Morse D, et al. Heme oxygen-ase/carbon monoxide signaling pathways: regulation and functional significance. Mol Cell Biochem. 2002;234/235:249-263.
44. Wagener FA, Volk HD, Willis D, et al. Different faces of the heme-heme oxygenase system in inflammation. Pharmacol Rev. 2003;55:551-557.
45. Maines MD. The heme oxygenase system: past, present, and future. Antioxid Redox Signal. 2004;6:797-801.
46. Soares MP, Lin Y, Anrather J, et al. Expression of heme oxygenase-1 can determine cardiac xenograft survival. Nature Med. 1998;4:1073-1077.
47. Ye J, Laychock SG. A protective role for heme oxygenase expression in pancreatic islets exposed to interleukin-1 beta. Endocrinology. 1998;139:4155-4163.
48. Yachie A, Niida Y, Wada T, et al. Oxidative stress causes enhanced endothelial cell injury in human heme oxygenase-1 deficiency. J Clin Invest. 1999;103:129-135.
49. Stocker R, Yamamoto Y, McDonagh AF, et al. Bilirubin is an antioxidant of possible physiological importance. Science. 1987;235:1043-1046.
50. Hopkins PN, Wu LL, Hunt SC, et al. Higher serum bilirubin is associated with decreased risk for early familial coronary artery disease. Arterioscler Thromb Vasc Biol. 1996;16:250-255.
51. Balla G, Jacob HS, Balla J, et al. Ferritin: a cytoprotective antioxidant strategem of endothelium. J Biol Chem. 1992;267:18148-18153.
52. Alam J, Igarashi K, Immenschuh S, et al. Regulation of heme oxygenase-1 gene transcription: recent advances and highlights from the International Conference (Uppsala, 2003) on Heme Oxygenase. Antioxid Redox Signal. 2004;6:924-933.
53. Exner M, Minar E, Wagner O, et al. The role of heme oxygenase-1 promoter polymorphisms in human disease. Free Radio Biol Med. 2004;37:1097-1104.
54. Brydun A, Watari Y, Yamamoto Y, et al. Reduced expression of heme oxygenase-1 in patients with coronary atherosclerosis. Hypertens Res. 2007;30:341-348.
55. Bainbridge SA, Smith GN. HO in pregnancy. Free Radic Biol Med. 2005;38:979-988.
56. Grosser N, Abate A, Oberle S, et al. Heme oxygenase-1 induction may explain the antioxidant profile of aspirin. Biochem Biophys Res Commun. 2003;308:956-960.
57. Bach F. Heme oxygenase-1: a therapeutic amplification funnel. FASEB J. 2005;19:1216-1219.
58. Schröder H. Novel pathways for an old drug: lipoxin A4 may mediate heme oxygenase-1 induction by aspirin. Am J Physiol Cell Physiol. 2005;289:C507-C508.
59. Yee EL, Pitt BR, Billiar TR, et al. Effect of nitric oxide on heme metabolism in pulmonary artery endothelial cells. Am J Physiol. 1996;271:L512-L518.
60. Motterlini R, Foresti R, Intaglietta M, et al. NO-mediated activation of heme oxygenase: endogenous cytoprotec-tion against oxidative stress to endothelium. Am J Physiol.1996;270:H107-H114.
61. Durante W, Kroll MH, Christodoulides N, et al. Nitric oxide induces heme oxygenase-1 gene expression and carbon monoxide production in vascular smooth muscle cells. Circ Res. 1997;80:557-564.
62. Polte T, Abate A, Dennery PA, et al. Heme oxygenase-1 is a cyclic GMP-inducible endothelial protein and mediates the cytoprotective action of nitric oxide. Arterioscler Thromb Vase Biol. 2000;20:1209-1215.
63. Bouton C, Demple B. Nitric oxide-inducible expression of heme oxygenase-1 in human cells-translation-independent stabilization of the mRNA and evidence for direct action of nitric oxide. J Biol Chem. 2000;275:32688-32693.
64. Oberle S, Abate A, Grosser N, et al. Heme oxygenase-1 induction may explain the antioxidant profile of pentaer-ithrityl trinitrate. Biochem Biophys Res Commun. 2002;290:1539-1544.
65. Nascimento-Silva V, Arruda MA, Barja-Fidalgo C, et al. Novel lipid mediator aspirin-triggered lipoxin A4 induces heme oxygenase-1 in endothelial cells. Am J Physiol. 2005;289:C557-C563.
66. Claria J, Serhan CN. Aspirin triggers previously undescribed bioactive eicosanoids by human endothelial cell-leukocyte interactions. Proc Natl Acad Sci USA. 1995;92:9475-9479.
67. Paul-Clark MJ, Van Cao T, Moradi-Bidhendi N, et al. 15-epi-Lipoxin A4-mediated induction of nitric oxide explains how aspirin inhibits acute inflammation. J Exp Med. 2004;200:69-78.
68. Fries JF, Williams CA, Bloch DA. The relative toxicity of nonsteroidal anti-inflammatory drugs. Arthritis Rheum.1991;34:1353-1360.
69. Singh G, Ramey DR, Morfeld D, et al. Comparative toxicity of non-steroidal anti-inflammatory agents. Pharmacol Ther. 1994;62:175-191.
70. Fries JF, Bruce B. Rates of serious gastrointestinal events from low dose use of acetylsalicylic acid, acetaminophen, and ibuprofen in patients with osteoarthritis and rheumatoid arthritis. J Rheumatol. 2003;30:2226-2233.
71. Lanas A, Scheiman J. Low-dose aspirin and upper gastrointestinal damage: epidemiology, prevention and reatment. Curr Med Res Opin. 2007;23:163-173.
72. Aburaya M, Tanaka K, Hoshino T, et al. Heme oxygenase-1 protects gastric mucosal cells against non-steroidal antiinflammatory drugs. J Biol Chem. 2006;281:33422-33432.
73. Lo SS, Lin SC, Wu CW, et al. Heme oxygenase-1 gene promoter polymorphism is associated with risk of gastric adenocarcinoma and lymphovascular tumor invasion. Ann Surg Oncol. 2007;14:2250-2256.
74. Becker JC, Grosser N, Schroder H, et al. Gastropro-tection by vitamin C-a heme oxygenase-dependent mechanism? Biochem Biophys Res Commun. 2003;312:507-512.
75. Wallace JL, Fiorucci S. A magic bullet for mucosal protection⋯ and aspirin is the trigger! Trends Pharmacol Sci. 2003;24:323-326.
76. Berndt G, Grosser N, Hoogstraate J, et al. AZD3582 increases heme oxygenase-1 expression and antioxidant activity in vascular endothelial and gastric mucosal cells. Eur J Pharm Sci. 2005;25:229-235.
77. Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal anti-inflammatory drugs. N Engl J Med. 1999;340:1888-1899.
78. Wallace JL, Miller MJ. Nitric oxide in mucosal defense:a little goes a long way. Gastroenterology. 2000;119:512-520.
79. Duley L, Henderson-Smart D, Knight M, et al. Antiplatelet drugs for prevention of pre-eclampsia and its consequences: systematic review. BMJ. 2001;322:329-333.
80. Grosser N, Hemmerle A, Berndt G, et al. The antioxidant defense protein heme oxygenase-1 is a novel target for statins in endothelial cells. Free Radic Biol Med. 2004;37:2064-2071.
81. Lee TS, Chang CC, Zhu Y, et al. Simvastatin induces heme oxygenase-1: a novel mechanism of vessel protection. Circulation. 2004;110:1296-1302.
82. Gueler F, Park JK, Rong S, et al. Statins attenuate ischemia-reperfusion injury by inducing heme oxygenase-1 in infiltrating macrophages. Am J Pathol. 2007;170:1192-1199.
83. Verheugt FW. Aspirin, the poor man's statin? Lancet. 1998;351:227-228.